BCHE Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P06276 |
---|---|
Clone Names | 80311206 |
Gene ID | 590 |
---|---|
Other Names | Cholinesterase, Acylcholine acylhydrolase, Butyrylcholine esterase, Choline esterase II, Pseudocholinesterase, BCHE, CHE1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7829c was selected from the Center region of human BCHE. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | BCHE |
---|---|
Synonyms | CHE1 |
Function | Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters. |
Cellular Location | Secreted |
Tissue Location | Detected in blood plasma (at protein level). Present in most cells except erythrocytes |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Mutant proteins of BCHE are responsible for suxamethonium sensitivity. Homozygous persons sustain prolonged apnea after administration of the muscle relaxant suxamethonium in connection with surgical anesthesia. The activity of pseudocholinesterase in the serum is low and its substrate behavior is atypical. In the absence of the relaxant, the homozygote is at no known disadvantage.
References
Primo-Parmo S.L., Bartels C.F.Am. J. Hum. Genet. 58:52-64(1996)Primo-Parmo S.L., Lightstone H.Pharmacogenetics 7:27-34(1997) Yen T., Nightingale B.N.Clin. Chem. 49:1297-1308(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.